, Sans!Rechute!Métastatique!4!SS7TSA,!Survie!Sans!Traitement!par!Suppression!Androgénique!4!SG,!Survie! Globale!4!SSpM,!Survis!Spécifique!de!la!Maladie!4!M+,!Métastase!4!Ggli,!ganglionnaire!4!RCS,!Radiothérapie!en!Condition!Stéréotaxique!4!TSA,!Traitement!par!Suppression!Androgénique! 4!conco,!concomitant!4!TEP7choline,!Tomographie!par!Émission!de!Positons!couplée!au!scanner!et!marquée!à!la!choline!4!SIB,!Simultaneous
, Survie'Sans'Rechute'Biochimique'(SSRB)'(critère'd'évaluation'principal
!(18)!(seul!essai!prospectif,!62!patients ,
, Survie'Sans'Rechute'Métastatique'(SSRM
, Temps'de'doublement'du'PSA''(TD>PSA)!
, Métastases'ganglionnaires'exclusives'versus'non'exclusives'
, Temps'de'doublement'du'PSA''(TD>PSA)!
, Bien!que!les!populations!ne!soient!pas!identiques,!les!SG!des!essais!rétrospectifs!publiés
, Délai'diagnostic'initial'-'rechute'oligométastatique
,
, ! ! Incidence'de'la'Résistance'à'la'Castration'
, 3%! (n=38)! et! 11,4%! des! cas! (n=13),! respectivement.! Seul! un! cas! (0,9%)! de!
)!est!un!essai!de!phase!II,!randomisé,!en!cours!d'inclusion,!qui!étudie! ,
,
,
! différencié! de! la! thyroïde,!bronchique!non!à!petites!cellules,!glioblastome!et!lymphome!folliculaire.!D'autre! part,! certaines! lésions! bénignes! sont! également! avides! de! PSMA! :! maladie! de! Paget ,
,
Clinical states in prostate cancer: toward a dynamic model of disease progression, Urology. 1 mars, vol.55, issue.3, pp.323-330, 2000. ,
Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up, The Lancet. 6 déc, vol.384, issue.9959, pp.2027-2062, 2014. ,
,
, Recommandations françaises du Comité de Cancérologie de l'AFU -Actualisation 2018-2020!: cancer de la prostate, vol.28, 2018.
Risk of Prostate Cancer-Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy, JAMA. 27 juill, vol.294, issue.4, pp.433-442, 2005. ,
A Systematic Review of the Role of ,
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and CastrationResistant Prostate Cancer, European Urology. 1 avr, vol.71, issue.4, pp.630-672, 2017. ,
,
, Oligometastases. JCO. 1 janv, vol.13, issue.1, p.10, 1995.
The biology and treatment of oligometastatic cancer, Oncotarget. 13 avr, vol.6, issue.11, pp.8491-524, 2015. ,
The Role of 11C-Choline and 18F-Fluorocholine Positron Emission Tomography (PET) and PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis, European Urology. 1 juill, vol.64, issue.1, pp.106-123, 2013. ,
,
American Society for Therapeutic Radiology and Oncology (ASTRO) and American College of Radiology ,
, Cancer colorectal métastatique | SNFGE.org -Société savante médicale française d'hépato-gastroentérologie et d'oncologie digestive
,
Oligometastases revisited, Nature Reviews Clinical ,
,
, Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature, European Urology. 1 mai, vol.67, issue.5, p.63, 2015.
Rôle de la radiothérapie en conditions stéréotaxiques dans la prise en charge des patients atteints d'un cancer de prostate oligométastatique, Bulletin du Cancer. 1 janv, vol.105, issue.1, p.5, 2018. ,
Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial, J Clin Oncol. 10 févr, vol.36, issue.5, pp.446-53, 2018. ,
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE). BMC Cancer, vol.29, p.20, 2017. ,
, , 2017.
,
Irradiation hypofractionnée du cancer de prostate!: quelles connaissances radiobiologiques en, 2017. ,
, , 2017.
,
,
Toxicity and quality of life after choline-PET/CT directed salvage lymph node dissection and adjuvant radiotherapy in nodal recurrent prostate cancer, Radiation Oncology. 12 août, vol.9, p.178, 2014. ,
Salvage Stereotactic Body Radiotherapy for Patients With Limited Prostate Cancer Metastases: Deferring Androgen Deprivation Therapy, Clinical Genitourinary Cancer. 1 mars, vol.11, issue.1, pp.27-32, 2013. ,
Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastases, Acta Oncol, vol.52, issue.8, pp.1622-1630, 2013. ,
Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years, European Urology. 1 févr, vol.67, issue.2, pp.299-309, 2015. ,
Salvage Stereotactic Body Radiotherapy for Patients With Prostate Cancer With Isolated Lymph Node Metastasis: A Single-Center Experience, Clinical Genitourinary Cancer. 1 août, vol.13, issue.4, pp.279-84, 2015. ,
, , vol.85
, Pelvic Lymph Node Dissection in Recurrent Prostate Cancer: Surgical and Early Oncological Outcome
, BioMed Research International, 2015.
Progression-free Survival Following Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Treatment-naive Recurrence: A Multi-institutional Analysis, European Urology. 1 janv, vol.69, issue.1, p.12, 2016. ,
Mid-term Outcomes Following Salvage Lymph Node Dissection for Prostate Cancer Nodal Recurrence Status Post-radical Prostatectomy, Eur Urol Focus. déc, vol.2, issue.5, p.31, 2016. ,
Pattern of Progression after Stereotactic Body Radiotherapy for Oligometastatic Prostate Cancer Nodal Recurrences, Benefits of Using Stereotactic Body Radiotherapy in Patients With Metachronous Oligometastases of Hormone-Sensitive Prostate Cancer Detected by, vol.28, 2016. ,
, Clinical Genitourinary Cancer, vol.15, issue.5, pp.773-82, 2017.
Oligometastases from prostate cancer: local treatment with stereotactic body radiotherapy (SBRT). BMC Cancer. 22 mai, vol.17, p.361, 2017. ,
Stereotactic body radiotherapy in oligometastatic prostate cancer patients with isolated lymph nodes involvement: a two-institution experience, World J Urol. janv, vol.35, issue.1, pp.45-54, 2017. ,
,
Prognostic Value of [18F]-Fluoromethylcholine Positron Emission Tomography/Computed Tomography Before Stereotactic Body Radiation Therapy for Oligometastatic Prostate Cancer, International Journal of Radiation Oncology*Biology*Physics. 1 juin, vol.101, issue.2, p.10, 2018. ,
Oligorecurrent Nodal Prostate Cancer: Long-term Results of an Elective Nodal Irradiation Approach, American Journal of Clinical Oncology, vol.41, issue.10, pp.960-962, 2018. ,
,
,
Stereotactic body radiotherapy for multisite extracranial oligometastases, Cancer, vol.118, issue.11, pp.2962-70, 2012. ,
Stereotactic body radiotherapy for oligometastases, The Lancet Oncology. 1 janv, vol.14, issue.1, pp.28-37, 2013. ,
Clinical Outcomes of Stereotactic Brain and/or Body Radiotherapy for Patients with Oligometastatic Lesions, Jpn J Clin Oncol. 1 août, vol.40, issue.8, pp.788-94, 2010. ,
,
Weichselbaum RR. The 46th David A. Karnofsky Memorial Award Lecture: Oligometastasis-From Conception to Treatment, Nat Rev Urol. janv, vol.14, issue.1, p.50, 2017. ,
MicroRNA Expression Characterizes Oligometastasis(es). PLoS One, vol.13 ,
Towards a molecular basis of oligometastatic disease: potential role of micro-RNAs, Clin Exp Metastasis, vol.31, issue.12, pp.340-52, 2014. ,
, Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017, vol.73, p.211, 2018.
Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA, a randomised, multicentre, non-blinded, vol.17, pp.727-764, 2016. ,
Choline-PET in prostate cancer management: The point of view of the radiation oncologist, Critical Reviews in Oncology/Hematology. 1 sept, vol.91, issue.3, pp.234-281, 2014. ,
Use of ,
, Choline PET-CT as a Noninvasive Method for Detecting Pelvic Lymph Node Status from Prostate Cancer and Relationship with Choline Kinase Expression, Clin Cancer Res. 15 déc, vol.17, issue.24, pp.7673-83, 2011.
Predicting the Outcome of Salvage Radiation Therapy for Recurrent Prostate Cancer After Radical Prostatectomy, J Clin Oncol. 20 mai, vol.25, issue.15, pp.2035-2076, 2007. ,
, , p.68
, Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer-Updated Diagnostic Utility, Sensitivity, Specificity, and Distribution of Prostatespecific Membrane Antigen-avid Lesions: A Systematic Review and Meta-analysis, European Urology, vol.14, issue.2019, p.30095
A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer, Eur Urol Oncol. févr, vol.2, issue.1, pp.47-76, 2019. ,
Detection Rate ! 87! of 18F-choline-PET/CT and 68Ga-PSMA-HBED-CC-PET/CT for Prostate Cancer Lymph Node Metastases with Direct Link from PET to Histopathology: Dependence on the Size of Tumor Deposits in Lymph Nodes, J Nucl Med. 25 janv, 2019. ,
68Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature, Clinical Physiology and Functional Imaging, vol.38, issue.6, pp.911-933, 2018. ,
68Ga-PSMA PET/CT in prostate cancer patients -patterns of disease, benign findings and pitfalls. Cancer Imaging, vol.18, 2018. ,
, AFU!:!Association!Française!d'Urologie!
, ASTRO!:!American'Society'of'Therapeutic'Radialogy'and'Oncology' BED!:!Dose!Biologiquement!Efficace! CaP!:!Cancer!de!la!Prostate! ! EAU!:!European'Association'of'Urology
, Gray!/!fraction! ! HIFU!:!High>Intensity'Focused'Ultrasound!
,
, ISUP!:!International'Society'of'Urological'Pathology!
, !Performans!Status! PSA!:!Prostate'Specific'Antigen! ! PSMA!:!Prostate>Specific'Membrane'Antigen!
, !Radiothérapie!en!Condition!Stéréotaxique! ! SIB!:!Simultaneous'Integrated'Boost!
, SSPL!:!Survie!Sans!Progression!Locale!
Uptake'Value!(valeurs!de!fixation!normalisée)! ,
, TSA!:!Traitement!par!Suppression!Androgénique!! ! VMAT!:!Volumetric'Modulated'Arc'Therapy!